GlassScriptPhysician profile
Jared A Kvapil
NPI 1972814663
$3,405.36
in general payments reported to CMS, 2019-2025
21 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $28.37 · 2022: $271 · 2023: $659 · 2024: $1,046 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,132.42 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $660.43 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Watchman |
| Abbott Laboratories | $504.51 | 2022-2025 | Xience Skypoint, Amplatzer Amulet |
| Amgen INC. | $221.44 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $127.63 | 2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $117.96 | 2019-2024 | |
| Medtronic Vascular, INC. | $116.30 | 2019 | |
| Novo Nordisk INC | $109.27 | 2024-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.65 | 2019-2025 | Lifevest |
| Genzyme Corporation | $79.06 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $59.33 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $33.62 | 2022-2024 | Farxiga |
| Impulse Dynamics (USA) INC. | $23.84 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.74 | 2025 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.15 | 2024 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.60 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $16.44 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $15.73 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.63 | 2024 | Livalo |
| Sanofi-Aventis U.S. LLC | $12.55 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Kvapil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.